Presentation AHA 2024 Routine spironolactone in Acute Myocardial Infarction, results from the CLEAR SYNERGY OASIS 9 trial Presenter: Sanjit S Jolly November 17, 2024 REGISTER for free or LOG IN to view this content Coronary CAD Pharma ACS/AMI Heart Failure Heart Failure Pharma Presentation AHA 2024 Up Next Presentation THT Abstracts 2025 Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction Presenter: Emmanuel Otabor February 11, 2025 More slides + Presentation THT Abstracts 2025 Disparities in MDD Incidence Between HFpEF and HFrEF Patients Presenter: Ibrahim Kamel February 11, 2025 Presentation THT Abstracts 2025 Clinical Outcomes Among Patients With HFpEF and Peripheral Arterial Disease Undergoing Revascularization Presenter: Phuuwadith Wattanachayakul February 11, 2025 We Recommend
Presentation THT Abstracts 2025 Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction Presenter: Emmanuel Otabor February 11, 2025
Presentation THT Abstracts 2025 Disparities in MDD Incidence Between HFpEF and HFrEF Patients Presenter: Ibrahim Kamel February 11, 2025
Presentation THT Abstracts 2025 Clinical Outcomes Among Patients With HFpEF and Peripheral Arterial Disease Undergoing Revascularization Presenter: Phuuwadith Wattanachayakul February 11, 2025